

Innovation at Work California




Total Direct and Indirect
Economic Output of the
Biopharmaceutical Sector

\$243.8 billion


Total Employment
Supported by the
Biopharmaceutical Sector

851,563



A majority of Americans agree that even if it brings no immediate benefits, basic scientific research that advances the frontiers of knowledge is necessary and should be supported by the federal government.

Local Perspective: San Francisco, CA



Keith Yamamoto, Ph.D., Vice
Chancellor for Science Policy and
Strategy; Vice Dean for Research,
School of Medicine, University of
California, San Francisco

"We are witnessing an accelerated understanding of basic biological mechanisms that will lead to revolutionary new approaches to treat and prevent disease... Federal investment is the building blocks for long-term, transformative scientific discoveries."



Californians who died from
Cardiovascular Disease in 2014

78,000

Total NIH Award Funding
(FY14)

\$3,410 million

Research in the Golden State

The Salk Institute of Biological Sciences, University of California, San Diego (UCSD), and Nimbus Therapeutics, La Jolla, CA

In a National Institutes of Health (NIH) and Department of Defense (DoD)-funded collaboration between the Salk Institute, UCSD and Nimbus Therapeutics, researchers are working to develop a new treatment to inhibit cancer growth by interrupting an enzyme vital to lipid synthesis.

University of California, Berkeley, Berkeley, CA

The National Science Foundation (NSF) is funding researchers at UC Berkeley who are investigating the role of cilia, hair-like structures on gut cells, in the relationship between bacteria and the body. Researchers hypothesize that cilia impacts the ability of bacteria to cause infections, illuminating a potential new avenue for therapeutics.

Genentech, Carlsbad, Carmichael, Fullerton, La Jolla, and Torrance, CA

Genentech is conducting phase III clinical trials to test the safety and efficacy of a new drug for multiple sclerosis (MS). The treatment is specifically intended for patients who have not experienced success with currently available therapies.

SOURCES: NATIONAL INSTITUTES OF HEALTH, PHARMACEUTICAL RESEARCH AND MANUFACTURES OF AMERICAN (PRMA), CENTERS FOR DISEASE CONTROL AND PREVENTION, A RESEARCH AMERICA SURVEY OF U.S. ADULTS CONDUCTED IN PARTNERSHIP WITH ZOGBY ANALYTICS IN JUNE 2016, CLINICALTRIALS.GOV, THE SALK INSTITUTE, NATIONAL SCIENCE FOUNDATION.